22/06/2026 Merck’s tulisokibart met primary and key secondary endpoints in a Phase 3 study in patiets with moderately to severely active UC FDA and EMA accepted cemdisiran regulatory submissions for review for the treatment of gMG Prolium Biosciences announced milestones in systemic sclerosis and refractory lupus nephritis Merck’s tulisokibart met primary and key secondary endpoints in a Phase 3 study in patiets with moderately to severely active UC (Ref) Merck announced posi